Braveheart Bio Targets $1.2 Billion Valuation in IPO
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
Archive
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
The mostly cash transaction would add controls for non-human accounts and agents to Cyera's broader data-security platform.
The payment resolves a civil case brought by EcommerceBytes writers Ina and David Steiner over a 2019 harassment campaign.
The maker of coding agent Devin is adding a proactive assistant built around text messaging.
The executive-search firm is adding an AI-focused recruiting team with startup customers.
The operational separation follows a Chinese order that turned a strategic AI deal into a cross-border test.
The rocket and satellite company entered Nasdaq trading at a valuation above $1.7 trillion.
The ChatGPT maker joined Anthropic in a high-stakes race to bring frontier AI companies to public markets.
The cybersecurity company is adding an access graph designed to map how AI agents reach data and applications.
The open-source testing company will strengthen security evaluation for enterprise agents in OpenAI Frontier.
The Seattle company's team and desktop-agent technology will support Claude's ability to operate software.
The all-stock transaction brings rockets, satellites, social media and artificial intelligence under one company.